The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Treatment Intensification for Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/39486 Release Date: November, 2023 Expiration Date: November, 2024 LEARNING OBJECTIVES: At the conclusion of these activities, participants will be able to: 1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations. 2. Discuss the concept of...

PARPi: Precision Medicine in Advanced Prostate Cancer (2023) CME Available: https://auau.auanet.org/node/39597 At the conclusion of this activity, the learner will be able to: 1. Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class. 2. Describe the role of PARPi treatment alone and in combination with other cancer based therapies. 3. Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late...

Prostate Cancer Treatment Intensification Moderator: Dr. Jay D. Raman Guest: Dr. Michael S. Cookson Acknowledgement: This podcast was funded by and in collaboration with AZ. All opinions are that of the faculty and do not necessarily reflect those of AstraZeneca. Release Date: 11/8/2023 Expiration Date: 11/8/2024

Update Series (2023) Lesson 33: A Critical Appraisal of the 2021 AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care...

Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/39088 At the conclusion of these activities, participants will be able to: 1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer. 2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics). 3. Understand opportunities to improve quality and...

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects CME Available: https://auau.auanet.org/node/39087 At the conclusion of these activities, participants will be able to: 1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy. 2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health,...

Genetic Testing and Stone Disease Co-host: Kyle Wood, MD Population analysis demonstrated that genetic conditions resulting in stone disease are magnitudes higher than those seen in clinical cohorts, suggesting underdiagnosis. Urologist play a unique role as we often times have many touch points with these patient given their presentation for stone disease. With the advancement of treatments, specifically in primary hyperoxaluria, it is essential that urologist play a more active role in...

Advances in ADT Part II: A Guide for Urologists CME Available: https://auau.auanet.org/node/39385 LEARNING OBJECTIVES After participating in this educational activity, participants will be able to: 1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC. 2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer. 3. Facilitate discussions with...

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice CME Available: https://auau.auanet.org/node/39292 After participating in this educational activity, participants will be able to: 1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline. 2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer. 3. Define M0 CRPC and the treatment options. 4. Identify clinically meaningful endpoints in...

AUA2023 Medical Student Forum

AUA2023: Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide CME Available: https://auau.auanet.org/node/38322 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/38312 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

Treatment for Hormone Sensitive Prostate Cancer CME Available: https://auau.auanet.org/node/38703 Treatment for Hormone Sensitive Prostate Cancer (2023), is an exciting new educational offering to update urologists on the latest advancements in the management of hormone sensitive prostate cancer (HSPC), including treatment intensification. This educational initiative is comprised of multiple formats, including a live virtual course, on-demand webcast, and a podcast. This live virtual...

Update Series (2023) Lesson 21: Management of Chronic Pelvic Pain in Men Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical...

AUA2023: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider CME Available: https://auau.auanet.org/node/38307 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation CME Available: https://auau.auanet.org/node/38327 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Merck & Co., Inc. Pfizer, Inc.

AUA2023: What the General Urologist Should Know about Care of Transgender Patients CME Available: https://auau.auanet.org/node/38342 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: Refractory Overactive Bladder: How To Select 3rd Line Therapies and Optimize Outcomes CME Available: https://auau.auanet.org/node/38287 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas Urovant Sciences, Inc.

AUA2023: Prostate Cancer Diagnosis CME Available: https://auau.auanet.org/node/38302 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and...

AUA2023: Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women CME Available: https://auau.auanet.org/node/38337/ CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice CME Available: https://auau.auanet.org/node/38317 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: AUA Guidelines on Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38297 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Diversity, Equity and Inclusion in Urology: What Do We Need to Know CME Available: https://auau.auanet.org/node/38332/ ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: The Changing Face of Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38292 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.